Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4237287 | 0.86 | MAOB (0.47) | HRH3KCNH2GRIN2B | |
| SCHEMBL1230853 | 0.83 | MEN1 (0.58) | MEN1KMT2AGAA | |
| SCHEMBL4240603 | 0.82 | HRH3 (0.51) | HRH3KCNH2 | |
| SCHEMBL278451 | 0.81 | HRH3 (0.71) | HRH3KCNH2GRIN1GRIN2B | |
| SCHEMBL2812600 | 0.81 | KMT2A (0.56) | MEN1KMT2AGAA | |
| SCHEMBL14507935 | 0.80 | HRH3 (0.54) | HRH3KCNH2GRIN1GRIN2BGAA | |
| SCHEMBL4238396 | 0.79 | HRH3 (0.53) | HRH3KCNH2 | |
| SCHEMBL4235476 | 0.79 | BCHE (0.47) | HRH3 | |
| SCHEMBL4255240 | 0.79 | HRH3 (0.51) | HRH3KCNH2 | |
| SCHEMBL14507943 | 0.78 | ALDH1A1 (0.56) | HRH3KCNH2GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| CN-101198604-A | NPY antagonists, their preparation and use | CEREP (FR) | 2008-06-11 | — | — | CN | disclosed |
| CN-1636980-A | Dipeptide nitrile cathepsin K inhibitors | NOVARTIS AG (CH) | 2005-07-13 | — | — | CN | disclosed |
| CN-1183122-C | Dipeptide nitrile cathepsin K inhibitors | ��˹��ŵ�� | 2005-01-05 | — | — | CN | disclosed |
| CN-1398260-A | Dipeptide nitrile cathepsin K inhibitors | NOVARTIS AG (CH) | 2003-02-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | HRH3 210/4885KCNH2 1304/4885MEN1 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.